Trial Profile
A Phase IV open, randomized, controlled study to evaluate the safety and immunogenicity of a pediatric presentation (0.25 ml) of the virosomal hepatitis A virus (HAV) vaccine HAVpur in healthy young children aged between, and including, 18 months to 47 months, using a 0/6 month immunization schedule.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Aug 2016
Price :
$35
*
At a glance
- Drugs Hepatitis A vaccine inactivated (Primary)
- Indications Hepatitis A
- Focus Pharmacodynamics
- Sponsors Crucell
- 30 Mar 2010 New trial record